KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Non Operating Income for 6 consecutive years, with $232000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 95.24% year-over-year to $232000.0, compared with a TTM value of $3.2 million through Dec 2025, down 77.23%, and an annual FY2025 reading of $3.2 million, down 77.23% over the prior year.
  • Non Operating Income was $232000.0 for Q4 2025 at Recursion Pharmaceuticals, down from $10.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $10.0 million in Q3 2025 and bottomed at -$11.3 million in Q1 2025.
  • Average Non Operating Income over 5 years is $1.9 million, with a median of $2.3 million recorded in 2022.
  • The sharpest move saw Non Operating Income soared 226800.0% in 2023, then tumbled 369.27% in 2025.
  • Year by year, Non Operating Income stood at $27000.0 in 2021, then surged by 12825.93% to $3.5 million in 2022, then plummeted by 46.36% to $1.9 million in 2023, then skyrocketed by 160.1% to $4.9 million in 2024, then crashed by 95.24% to $232000.0 in 2025.
  • Business Quant data shows Non Operating Income for RXRX at $232000.0 in Q4 2025, $10.0 million in Q3 2025, and $4.3 million in Q2 2025.